<?xml version="1.0" encoding="UTF-8"?>
<p>Traditionally, such men were managed with androgen deprivation therapy (ADT) alone, via medical or surgical castration.
 <xref rid="R2" ref-type="bibr">2</xref> Unfortunately, the median time to the emergence of a castrate resistant state is in the order of 11–18 months, limiting overall survival (OS) to 3.5 years.
 <xref rid="R3" ref-type="bibr">3 4</xref> Promisingly, the reported OS in this group has now risen to a median of 4.8 years with the addition of upfront systemic agents, such as docetaxel, enzalutamide, abiraterone acetate or apalutamide.
 <xref rid="R5" ref-type="bibr">5–9</xref>
</p>
